Atypical cannabinoid ligands O-1602 and O-1918 administered chronically in diet-induced obesity

in Endocrine Connections
Correspondence: Deanne Hryciw, Email: d.skelly@griffith.edu.au

Atypical cannabinoid compounds O-1602 and O-1918 are ligands for the putative cannabinoid receptors G protein-coupled receptor 55 and G protein-coupled receptor 18. The role of O-1602 and O-1918 in attenuating obesity and obesity-related pathologies is unknown. Therefore, we aimed to determine the role that either compound had on body weight and body composition, renal and hepatic function in diet-induced obesity. Male Sprague Dawley rats were fed a high fat diet (40% digestible energy from lipids) or a standard chow diet for 10 weeks. In a separate cohort, male Sprague Dawley rats were fed a high-fat diet for 9 weeks and then injected daily with 5mg/kg O-1602, 1mg/kg O-1918 or vehicle (0.9% saline/ 0.75% Tween 80) for a further 6 weeks. Our data demonstrated that high fat feeding up-regulates whole kidney G protein-receptor 55 expression. In diet-induced obesity, we also demonstrated O-1602 reduces bodyweight, body fat and improves albuminuria. Despite this, treatment with O-1602 resulted in gross morphological changes in the liver and kidney. Treatment with O-1918 improved albuminuria but did not alter bodyweight or fat composition. In addition, treatment with O-1918 also up-regulated circulating pro-inflammatory cytokines including IL-1α, IL-2, IL-17α, IL-18 and RANTES as well as plasma AST. Thus O-1602 and O-1918 appear not to be suitable treatments for obesity and related co-morbidities, due to their effects on organ morphology and pro-inflammatory signalling in obesity.

If the inline PDF is not rendering correctly, you can download the PDF file here.

 

     European Society of Endocrinology

     Society for Endocrinology

Article Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 207 207 207
PDF Downloads 63 63 63

Altmetrics

Related Articles

PubMed

Google Scholar